We are live on ! Find out more
ACM

ACT Capital Management Portfolio holdings

AUM $153M
This Fund
S&P 500
This Quarter Est. Return
+9.63%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$193M
AUM Growth
-$1.65M
Cap. Flow
+$718
Cap. Flow %
0%
Top 10 Hldgs %
60.41%
Holding
141
New
23
Increased
22
Reduced
12
Closed
32

Top Buys

Rank Stock Value
1
INMB icon
INmune Bio
INMB
+$5.31M
2
STAA icon
STAAR Surgical
STAA
+$5.12M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$2.44M
4
NVNO
enVVeno Medical
NVNO
+$1.94M
5
CVX icon
Chevron
CVX
+$1.6M

Top Sells

Rank Stock Value
1
FLNA
Filana Therapeutics
FLNA
+$3.85M
2
U icon
Unity
U
+$3.33M
3
SKIN icon
SkinHealth Systems
SKIN
+$2.9M
4
FFIV icon
F5
FFIV
+$2.71M
5
NVAX icon
Novavax
NVAX
+$2.19M

Sector Composition

Rank Sector Weight
1 Healthcare 78.61%
2 Financials 5.86%
3 Technology 3.93%
4 Communication Services 3.41%
5 Consumer Discretionary 1.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STAA icon
1
STAAR Surgical
STAA
$1.14B
$34.5M 17.87%
268,200
+36,600
+16% +$5.12M
ARCT icon
2
Arcturus Therapeutics
ARCT
$178M
$21.8M 11.27%
455,300
– –
CLSD
3
DELISTED
Clearside Biomedical
CLSD
$14.8M 7.67%
164,500
+333
+0.2% +$29.4K
ARWR icon
4
Arrowhead Research
ARWR
$12.2B
$12.1M 6.28%
194,000
-14,600
-7% -$945K
TRIL
5
DELISTED
Trillium Therapeutics Inc.
TRIL
$8.18M 4.24%
466,000
+1,000
+0.2% +$11.7K
FUBO icon
6
FuboTV Inc
FUBO
$314M
$6.08M 3.15%
21,142
-1,191
-5% -$390K
UPST icon
7
Upstart Holdings
UPST
$2.89B
$5.41M 2.8%
17,100
-7,700
-31% -$1.52M
INMB icon
8
INmune Bio
INMB
$50.5M
$5.34M 2.77%
+275,000
New +$5.31M
IDYA icon
9
IDEAYA Biosciences
IDYA
$3.47B
$4.42M 2.29%
173,500
+104,300
+151% +$2.44M
AUPH icon
10
Aurinia Pharmaceuticals
AUPH
$1.95B
$3.98M 2.06%
180,000
+17,500
+11% +$278K
AWH
11
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$3.67M 1.9%
75,381
– –
AFRM icon
12
Affirm
AFRM
$26.3B
$2.92M 1.51%
24,500
+19,500
+390% +$1.56M
NKTR icon
13
Nektar Therapeutics
NKTR
$2.47B
$2.9M 1.5%
10,767
– –
NTRA icon
14
Natera
NTRA
$39.3B
$2.89M 1.5%
25,900
– –
NVNO
15
enVVeno Medical
NVNO
$7.39M
$2.73M 1.41%
+7,500
New +$1.94M
ICAD
16
DELISTED
iCAD Inc
ICAD
$2.41M 1.25%
224,500
+2,500
+1% +$32.5K
ATRA icon
17
Atara Biotherapeutics
ATRA
$76.9M
$2.09M 1.08%
4,676
– –
KRYS icon
18
Krystal Biotech
KRYS
$9.64B
$2.09M 1.08%
40,000
+20,925
+110% +$1.24M
NUAN
19
DELISTED
Nuance Communications, Inc.
NUAN
$2.06M 1.07%
37,500
– –
TGTX icon
20
TG Therapeutics
TGTX
$7.64B
$2M 1.04%
60,000
+5,000
+9% +$155K
UTHR icon
21
United Therapeutics
UTHR
$22B
$1.94M 1%
10,500
– –
IKT icon
22
Inhibikase Therapeutics
IKT
$377M
$1.92M 0.99%
168,333
+22,500
+15% +$304K
MYOV
23
DELISTED
Myovant Sciences Ltd.
MYOV
$1.91M 0.99%
85,000
-2,500
-3% -$54.9K
AFMD
24
DELISTED
Affimed
AFMD
$1.74M 0.9%
28,130
-630
-2% -$41.5K
NGNE icon
25
Neurogene
NGNE
$718M
$1.73M 0.9%
11,950
– –
1
2 3 4 5

Similar funds

BCI
Blue Capital Inc Omaha, Nebraska $153M AUM 28.69% 1-Year Est. Return
APW
Atlantic Private Wealth Chapel Hill, North Carolina $153M AUM 15.75% 1-Year Est. Return
DAM
Doheny Asset Management Los Angeles, California $153M AUM 42.04% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $153M AUM 16.24% 1-Year Est. Return
RHAM
Round Hill Asset Management Pasadena, California $153M AUM 6.67% 1-Year Est. Return
RFN
Redwood Financial Network Solon, Ohio $153M AUM 17.17% 1-Year Est. Return
SGM
Sellaronda Global Management New York $152M AUM 2.1% 1-Year Est. Return
HWM
Horizons Wealth Management Asheville, North Carolina $152M AUM 9.43% 1-Year Est. Return

ACT Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, ACT Capital Management held 141 positions worth $193M, down 0.85% from $195M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

ACT Capital Management's Q3 2021 filing shows 23 new, 22 increased, 12 reduced and 32 closed positions. Its largest new stake was INmune Bio: 275,000 shares worth $5.34M. The largest sale was Filana Therapeutics, an estimated $3.85M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 80% a quarter earlier, followed by Financials and Technology.

  • ACT Capital Management's largest Q3 2021 buy was INmune Bio: 275,000 shares worth $5.34M.
  • ACT Capital Management added most to STAAR Surgical in Q3 2021, an estimated $5.12M increase.
  • ACT Capital Management's biggest Q3 2021 reduction was Unity, cutting an estimated $3.33M.
  • ACT Capital Management fully exited Filana Therapeutics in Q3 2021, selling an estimated $3.85M.
  • ACT Capital Management's ten largest holdings make up 60% of its $193M portfolio in Q3 2021.
  • ACT Capital Management opened 23 new positions and closed 32 in Q3 2021.
  • ACT Capital Management's portfolio value fell 0.85% quarter-over-quarter to $193M.

Based on ACT Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.